Respiratory Research Unit, Complexo Hospitalario Universitario & Instituto de Investigación Biomédica de A Coruña (INIBIC), Spain.
Ther Adv Respir Dis. 2011 Feb;5(1):29-40. doi: 10.1177/1753465810387810. Epub 2010 Nov 8.
Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long-acting bronchodilators is recommended as more effective and convenient than short-acting bronchodilators, because the long-acting agents provide greater bronchodilator efficacy and symptomatic relief, increased tolerance to exercise, and improved rate of exacerbations and quality of life test scores. Dosing regimens requiring less frequent dosing also provide improved treatment compliance. Indacaterol is a novel once-daily ultra-long-acting β(2)-agonist bronchodilator now approved in the European Union for maintenance bronchodilator treatment of airflow obstruction in adult patients with COPD, to be administered as 150 or 300 microg once-daily dose by means of a single-dose dry powder inhaler. This review focuses on providing a clinical practice-oriented synopsis of the data generated from the randomized trials during the clinical development of indacaterol, published as of the time of writing. Indacaterol has been shown to provide effective 24-h bronchodilation and a fast onset of action, with an efficacy at least comparable or superior to current bronchodilator therapy standards and with a favourable safety and tolerability profile within the β(2)-agonist drug class.
目前慢性阻塞性肺疾病（COPD）管理指南确立了支气管扩张剂药物是该疾病症状治疗的核心。长效支气管扩张剂的常规治疗比短效支气管扩张剂更有效和方便，因为长效药物提供了更大的支气管扩张效果和症状缓解，增加了对运动的耐受性，并改善了恶化率和生活质量测试评分。需要较少频繁剂量的剂量方案也提供了更好的治疗依从性。茚达特罗是一种新型的每日一次超长效β(2)-激动剂支气管扩张剂，现已在欧盟获得批准，用于维持气流阻塞的成年 COPD 患者的支气管扩张治疗，以每日一次 150 或 300μg 的单剂量干粉吸入器给药。这篇综述重点提供了从茚达特罗临床开发期间的随机试验中生成的数据的临床实践导向概述，截至撰写时已发表。茚达特罗已被证明可提供有效的 24 小时支气管扩张和快速作用开始，其疗效至少与当前的支气管扩张剂治疗标准相当或更优，并且在β(2)-激动剂药物类别中具有良好的安全性和耐受性。
